Official Title
A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)
Brief Summary

This study is an adaptive, randomized, open-label, controlled clinical trial, in collaboration with countries around the world through the World Health Organization.

Detailed Description

Subjects will be randomized, across one, two, three or up to four separate randomizations, to
receive either standard-of-care products or the study medication plus standard of care, while
being hospitalized for COVID-19.

Randomization WHO: Imatinib vs Infliximab vs Artesunate vs Standard of care

Randomization Dex: Dexamethasone vs Standard of care

Randomization LSALT: LSALT Peptide vs Standard of care

Hospitalized subjects will require blood sampling for screening and on days 1 and 5.

Active, not recruiting
COVID-19

Drug: Artesunate

2.4 mg/kg at 0 hours, 12 hours, 24 hours, and then daily for a total of 7 days plus standard of care

Drug: Imatinib

400 mg enterally daily for 14 days plus standard of care

Drug: Infliximab

5 mg/kg IV given one time, over 2 hours plus standard of care

Drug: Dexamethasone

6 mg IV/oral for a further five days, followed by a five day taper of 4 mg x 2 days and 2 mg x 3 days, for a total 20 day steroid course. If randomized to standard of care, discontinue the corticosteroid on day 10

Drug: LSALT Peptide

5 mg , 2 hour IV infusion once daily for up to 14 consecutive days

Eligibility Criteria

Inclusion Criteria:

Each participant must meet all of the following inclusion criteria to participate in this
study:

1. ≥ 18 years of age

2. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other
commercial or public health assay in any specimen, within 14 days prior to
randomization.

3. Hospitalized at a participating centre

4. Primary reason for hospitalization or subsequent in-hospital illness is because of
acute COVID19 infection

5. First admission for acute COVID19

In addition, there will be the below intervention-specific inclusion:

Randomization WHO will have no other specific inclusion criteria.

Randomization LSALT will have no other specific inclusion criteria.

Randomization Dex will have the following specific inclusion criteria

1. On 10 days of steroid course and

2. Receiving any supplemental oxygen for 10 days

Exclusion Criteria:

All participants meeting any of the following exclusion criteria at baseline will be
excluded from participation in this study:

1. Anticipated transfer to another hospital, within 72 hours, which is not a study site

2. Expected to not survive beyond 24 hours

3. Receiving one of the study drugs at time of enrolment

In addition, there will be the below intervention-specific exclusions:

Randomization WHO:

These will be drug-specific exclusions; patients will still be eligible for randomization
in Randomization WHO to the other available study drugs (in randomization WHO or subsequent
randomizations).

Artesunate:

1. Known hypersensitivity to artesunate

Imatinib:

1. Pregnant or breastfeeding;

2. Known hypersensitivity to imatinib;

3. Liver transaminases (either ALT or AST) > 5x upper limit of normal

Infliximab:

1. Known moderate or severe heart failure, per treating clinician, defined as New York
Heart Association (NYHA) class III or IV

2. Known or suspected active tuberculosis

3. Known hypersensitivity to infliximab

Randomization LSALT:

1. Known hypersensitivity or prior use of LSALT peptide.

2. Pregnant or breastfeeding

Randomization Dex:

1. Receiving glucocorticoids for a specific, non-COVID-19 indication

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Canada
Locations

Peter Lougheed Centre
Calgary, Alberta, Canada

Foothills Medical Centre
Calgary, Alberta, Canada

Rockyview General Hospital
Calgary, Alberta, Canada

South Health Campus
Calgary, Alberta, Canada

Royal Alexandra Hospital
Edmonton, Alberta, Canada

Misericordia Community Hospital
Edmonton, Alberta, Canada

University of Alberta Hopsital
Edmonton, Alberta, Canada

Grey Nuns Community Hospital
Edmonton, Alberta, Canada

Interior Health Royal Inland Hospital
Kamloops, British Columbia, Canada

Lions Gate Hospital
North Vancouver, British Columbia, Canada

Richmond Hospital
Richmond, British Columbia, Canada

Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia
Vancouver, British Columbia, Canada

St Paul's Hospital
Vancouver, British Columbia, Canada

Island Health - Royal Jubilee Hospital
Victoria, British Columbia, Canada

Island Health - Victoria General Hospital
Victoria, British Columbia, Canada

Island Health - Nanaimo Regional General Hospital
Victoria, British Columbia, Canada

St. Boniface Hospital
Winnipeg, Manitoba, Canada

Health Sciences Centre
Winnipeg, Manitoba, Canada

Grace General Hospital
Winnipeg, Manitoba, Canada

Eastern Regional Health Authority
Saint John's, Newfoundland and Labrador, Canada

Nova Scotia Health Authority
Halifax, Nova Scotia, Canada

Royal Victoria Regional Health Centre
Barrie, Ontario, Canada

William Osler Health System - Brampton Civic Hospital
Brampton, Ontario, Canada

William Osler Health System - Etobicoke General Hospital
Etobicoke, Ontario, Canada

St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada

St.Joseph's Health Care
London, Ontario, Canada

University Hospital
London, Ontario, Canada

Victoria Hospital
London, Ontario, Canada

Markham Stouffville Hospital
Markham, Ontario, Canada

Trillium Health Partners -Mississauga Site
Mississauga, Ontario, Canada

Trillium Health Partners-Credit Valley Hospital
Mississauga, Ontario, Canada

The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada

Hôpital Montfort
Ottawa, Ontario, Canada

The Ottawa Hospital - Civic Campus
Ottawa, Ontario, Canada

Queensway Carleton Hospital
Ottawa, Ontario, Canada

Niagara Health
Saint Catharines, Ontario, Canada

Scarborough Health Network - Centenary Hospital
Scarborough, Ontario, Canada

Scarborough Health Network - General Hospital
Scarborough, Ontario, Canada

Scarborough Health Network - Birchmount Hospital
Scarborough, Ontario, Canada

Thunder Bay Regional Health Sciences Centre
Thunder Bay, Ontario, Canada

North York General Hospital
Toronto, Ontario, Canada

Humber River Hospital
Toronto, Ontario, Canada

Michael Garron Hospital
Toronto, Ontario, Canada

Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada

St. Michael's Hospital
Toronto, Ontario, Canada

Mount Sinai Hospital
Toronto, Ontario, Canada

Toronto Western Hospital
Toronto, Ontario, Canada

Unity Health Toronto - St. Joseph's Health Centre
Toronto, Ontario, Canada

Centre Hospitalier de l'Université de Montréal (CHUM)
Montréal, Quebec, Canada

McGill University Health Centre-Glen Site Royal Victoria Hospital
Montréal, Quebec, Canada

CHU de Québec - Université Laval
Québec, Quebec, Canada

Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval
Québec, Quebec, Canada

Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke
Sherbrooke, Quebec, Canada

Srinivas Murthy, MD, Principal Investigator
Provincial Health Services Authority

Sunnybrook Health Sciences Centre
NCT Number
Keywords
Artesunate
infliximab
imatinib
dexamethasone
SARS-CoV-2
LSALT Peptide
MeSH Terms
COVID-19
Artesunate
Dexamethasone
Infliximab
Imatinib Mesylate